245 related articles for article (PubMed ID: 36036563)
1. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
2. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
[TBL] [Abstract][Full Text] [Related]
3. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
[TBL] [Abstract][Full Text] [Related]
4. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
[TBL] [Abstract][Full Text] [Related]
5. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
6. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
7. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Ninomaru T; Hata A; Hara S; Komatsu M
Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
10. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
[TBL] [Abstract][Full Text] [Related]
12. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
13. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
14. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
[TBL] [Abstract][Full Text] [Related]
15. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
[TBL] [Abstract][Full Text] [Related]
16. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
[TBL] [Abstract][Full Text] [Related]
17. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Kusaba Y; Takeda Y; Abe S; Tsukada A; Naka G
Medicine (Baltimore); 2022 Aug; 101(32):e29682. PubMed ID: 35960133
[TBL] [Abstract][Full Text] [Related]
18. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
[TBL] [Abstract][Full Text] [Related]
19. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]